Table.

Summary description of molecular subtypes of medulloblastoma

Molecular Subtype	Approximate percent of patients	Typical patient age	Typical Histology	Cytogenetic markers	Molecular markers	Clinical strategy
WNT	10%	Older childhood	Classic	Monosomy 6	Beta-catenin	Reduction in therapy
SHH	25%	Infant and Adult	Desmoplastic or Classic	9q loss	SFRP1[47]or GAB1[50]	SHH pathway inhibitors
Group C	30%	Childhood	Classic or Anaplastic	Isochromosome 17q	MYC activation in 50% of this subtype	Intensified therapy, novel therapeutics
Group D	35%	Childhood	Classic or Anaplastic	Isochromosome 17q	Unknown	Research focus needed